Welcome to our dedicated page for Nls Pharmaceutics news (Ticker: NLSP), a resource for investors and traders seeking the latest updates and insights on Nls Pharmaceutics stock.
NLS Pharmaceutics Ltd. (NLSP) generates news that reflects both its historical role as a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders and its transformation through a merger with Kadimastem Ltd. into NewcelX Ltd. Company announcements and SEC filings describe a shift from a pure CNS small-molecule focus toward an integrated platform that also encompasses cell therapies for neurodegenerative and metabolic diseases.
News items associated with NLSP and the subsequent NewcelX name cover several recurring themes. Transaction-related updates include the approval and closing of the merger with Kadimastem, the 1-for-10 reverse share split, the name change to NewcelX Ltd., and the transition of the Nasdaq listing from NLSP to the new symbol NCEL. These releases explain the exchange ratio between NLS and Kadimastem shareholders, the resulting ownership structure, and the rationale for combining small-molecule and cell therapy pipelines.
Pipeline and R&D news highlights programs such as AstroRx® for ALS, the IsletRx stem cell–derived therapy for insulin-dependent diabetes, and the DOXA small-molecule platform for CNS and neurodegenerative indications. Announcements describe preclinical and clinical milestones, intellectual property developments such as a Hong Kong patent for IsletRx-related cell-selection and enrichment technology, and expansion of the DOXA platform through the AEX-6xx series developed with Aexon Labs.
Additional coverage includes strategic collaborations and governance updates. Examples are the collaboration framework between Kadimastem and TargetGene for gene-edited cell therapies, continued support from the BIRD Foundation for the ITOL-102 diabetes program, and appointments to leadership roles and the Scientific Advisory Board at NewcelX. For readers tracking NLSP-related news, this page offers a consolidated view of historical NLS announcements and the ongoing evolution of the combined company under the NewcelX name and NCEL ticker.
NLS Pharmaceutics, a clinical-stage biopharmaceutical company, has announced a new patent application for dual orexin receptor agonists (DOXA), developed with Aexon Labs, targeting narcolepsy and neurodegenerative diseases like Parkinson's. These non-sulfonamide compounds are designed to reduce side effects and improve patient safety. The molecules enhance neurotransmitter release and protect neuronal health by modulating orexin receptors and inhibiting cathepsin H (CTSH), offering potential therapeutic benefits for sleep regulation and neurodegeneration. This patent represents a significant advancement in addressing unmet medical needs in both narcolepsy and neurodegenerative diseases.
NLS Pharmaceutics announced promising results from study KO-874, presented at the American Society of Clinical Psychopharmacology. The study evaluated mazindol's neuroprotective effects in a narcoleptic-like rat model. Key findings showed that a 3 mg/kg dose of mazindol significantly mitigated circadian activity reduction caused by OX-B-SAP lesions and restored activity levels to normal. Lower doses were less effective. The study highlights mazindol's potential utility in treating disorders like narcolepsy. Further clinical development is supported by these results.
NLS Pharmaceutics (NASDAQ: NLSP) announced it received an additional staff determination letter from Nasdaq on May 22, 2024, notifying the company of its non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. This additional delinquency serves as a separate basis for potential delisting. Previously, on April 19, 2024, NLS was informed of potential delisting due to failing to maintain a $1 bid price per share. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 4, 2024, to appeal the delisting determination and present its plans to regain compliance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.